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Abstract 
Metabolic syndrome (MetS) is a cluster of conditions, each of which
represents a risk factor for cardiovascular disease: central
obesity,  hyperglycemia, dyslipidemia and hypertension. In different
recent studies, MetS has been associated with an accelerate cognitive
decline in the elderly. The aim of our research was to investigate the
relationship between MetS and cognitive performance in 174 italian
elderly people living in Val Cenischia (Piedmont, Italy). Mini mental
state examination (MMSE) has been administered to assess the cog-
nitive status of all participants. The prevalence of MetS is 50.3% (51.3
and 49.5% for males and females, respectively). Our results confirm
the association between MetS and worse cognitive performance in the
elderly: an increased number of MetS components  is associated with
an increased risk of developing cognitive impairment (odds
ratio=1.54; confidence interval 95%:1.04-2.28; P<0.05).
Introduction
Metabolic syndrome (MetS) is a cluster of conditions, each of which
represents a risk factor for cardiovascular disease: central
obesity, hyperglycemia, dyslipidemia and hypertension. MetS can be
diagnosed when three or more of these criteria are present [National
Cholesterol Education Program - Adult Treatment Panel III (NCEP ATP
III) criteria]: waist circumference ≥102 cm (male) or ≥88 cm
(female); triglycerides >150 mg/dL or lipid lowering drug use; high-
density lipoprotein cholesterol (HDL-C) <40 mg/dL (male) or <50
mg/dL (female); blood pressure >130/85 mmHg or antihypertensive
drug use; fasting plasma glucose >100 mg/dL or hypoglycemic drug
use.1 Any of these conditions and MetS itself have been associated to
an increased risk of age-related cognitive decline, Alzheimer’s disease
(AD) and vascular dementia.2-6
The aim of our research was to assess the prevalence of MetS in a
sample of elderly people belonging to a rural alpine community and
investigate the relationship between MetS and cognitive performance.
The research has been reviewed and received ethics approval by the
Bioethics Committee of the University of Turin, Italy.
Materials and Methods
We evaluated 174 people (97 women and 77 men) aged 60 and over
(mean age 73.4±7.3 years for males and 75.1±8.7 years for females)
living in the villages of Venaus, Mompantero and Novalesa (Cenischia
Valley, Piedmont, Italy). They were recruited through the local health-
care service (ASL TO3) and they all are people whose families have
been living in the valley for at least three generations. Blood samples
were collected from each participant in the morning to determine plas-
ma total, HDL-C, triglycerides and fasting plasma glucose level. Blood
pressure, waist circumference, height and weight were measured and
a detailed pharmacological anamnesis was recorded in order to define
current assumption of drugs.
Cognitive status was assessed with the mini mental state examina-
tion (MMSE) which is the screening test most widely used for cogni-
tive impairment (CI).7 MMSE allows the quantification of cognitive
abilities and their changes over time and it has a good reliability (sen-
sitivity=87%; specificity=82%). The MMSE total combines scores from
five cognitive domains (orientation, language and comprehension,
memory, attention, calculation and praxis), where each domain con-
tributes approximately equal weight to the overall score. The total
score was corrected by age and educational level using the score-
adjustment coefficients proposed by Magni et al. in the 1996.8 A score
<24.0 has been accepted as indicating the presence of CI.9
All data were entered into Excel® spreadsheets (Microsoft 2007)
and analyzed with SPSS Statistics 20.0. 
Results
The characteristics of the participants with (MMSE<24.0) and with-
out CI (MMSE≥24.0) are resumed in Table 1. The average HDL-C level
is lower among people with CI compared to people without CI (48.7 vs
55.9 mg/dL, P=0.034). HDL-C levels lower than the recommended val-
ues (<40 mg/dL for males and <50mg/dL for females) are significantly
associated with CI [odds ratio (OR)=3.22; P=0.017)]. In our sample,
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however, the average total cholesterol (TC) level is lower in the group
with CI and this could account for the association between low HDL-C
and CI. In fact, if we compare the TC/HDL-C ratio between the two
groups we cannot find any difference.
The group with CI shows an increased number of MetS components
(NCEP ATPIII criteria) compared to the group without CI (2.9 vs 2.1;
P=0.015).
All the variables with statistical significance (P<0.05) in the univari-
ate analysis were introduced into multivariate logistic regression
analysis that showed CI is associated with age (OR=1.087; P=0.009)
and an increased number of MetS components (OR=1.54; P=0.042)
(Table 2).
Discussion
MetS is characterized by a clustering of risk factors for cardiovascu-
lar disease and its prevalence, similar to that for cognitive disorders,
increases dramatically with age. A growing body of epidemiological evi-
dence suggested that MetS components may be important in the devel-
opment of age-related cognitive decline, vascular dementia, and
AD.10,11 Several possible mechanisms may explain an association
between MetS and CI including microvascular and macrovascular dis-
ease, inflammation, adiposity, and insulin resistance.12 Our study has
some limitations, the most important the small sample size, but our
results are consistent with a recent study that found an association
between MetS, the number of its components and risk of developing CI
in older women from clinical centers.13 In fact, although the prevalence
of MetS in our sample is not significantly different between people with
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Table 2. Multivariate association of age and numbers of National
Cholesterol Education Program - Adult Treatment Panel III cri-
teria with cognitive impairment. 
OR, odds ratio; CI, confidence interval; NCEP ATPIII, National Cholesterol Education Program - Adult
Treatment Panel III.
Table 1. Characteristics of 174 participants with (mini mental state examination<24.0) and without cognitive impairment (mini mental
state examination≥24.0). 
DF, degree of freedom; n.s., not significant; BMI, body mass index; AO, abdominal obesity (defined by a waist circumference ≥102 cm for males and ≥88 cm for females); HTN, hypertension (BP>135/85 mmHg and/or
antihypertensive drugs); BP, blood pressure; NIDDM, non insulin-dependent diabetes mellitus; TG, triglycerides; HTG, hypertriglyceridemia (TG>150 mg/dL and/or lipid-lowering drugs); TC, total cholesterol; HTC,
hypercholesterolemia (TC≥240 mg/dL and/or lipid-lowering drugs); HDL-C, high density lipoprotein cholesterol (Low HDL-C when <40 mg/dL for males and <50 mg/dL for females); MetS, metabolic syndrome; NCEP
ATPIII, National Cholesterol Education Program - Adult Treatment Panel III.
Values are mean±standard deviation or percentages (n=number of cases).
No
n c
om
me
rci
al 
us
e o
nly
and without CI, both univariate and multivariate statistics show an
association between an increased number of MetS components and CI.
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